BMRA

Biomerica, Inc. | Healthcare

6.19658%

Analisi Pre-Earnings (Antonio AI)

2025-12-18
Sentiment
85.0/100
Salute

Caution

Verdict

The story is fantastic - major partnerships and global approvals are lighting up the news feed. 🔥 But the books are a complete mystery; flying blind into earnings is for gamblers, not sharks. ⚠️

Catalysts
  • Major U.S. commercialization partnership with Henry Schein for the inFoods® IBS test.
  • Constant stream of international approvals (Egypt, UAE) and key executive hires, building a strong growth narrative.
Rischi
  • Complete lack of financial data makes assessing solvency impossible. High potential for significant cash burn and future dilution.
Approfondisci con Antonio
Valutazione
P/E (TTM)-1.9095373064295487
Forward P/E-1.9095373064295487
P/S1.5539428746928747
Market Cap7130360
Finanze & Debito
CashNone
DebtNone
Debt/Equity0.07235693501454898
Current Ratio3.4843473124630835
Redditività
ROE-0.7343781394414306
Profit Margin-0.7483619983619983
Operating Margin-1.0002047502047502
Rev. Growth0.014234875444839857
Ultime News (Context per AI)